Thanks for the comparison cashpot - well thought out.
In other words, there is just no comparison between TENS and BIEL's products. Apples and Oranges. Perhaps Sanofi would like a total lock on non-chemical pain management devices. Hadn't thought of that. Too obvious, I guess. I frequently thought J&J would be a logical player given the potential loss in sales of Tylenol 1 through 4 when common sense prevails about chemical drugs and their side-effects.
I also think about it this way - did the FDA have a devices division 10 years ago? It's a process and BIEL is very close. I also wonder if the FDA is perhaps working to a schedule of 60 day timing tranches? 60 days to May 21 for public comments to its Proposed Order - 60 days to July 21, or so, for it to review those comments and edit the Proposed Order to Final Oder? Just wondering.